NZ Hepatitis Research Review Issue 28

In this issue:

Modifying RBV dose with Viekira Pak: no impact on SVR12
Offer HCV treatment to PWID
Achieving SVR improves PROs
DAAs have impacted on the need for LT in HCV
HCV linked to an increased risk of CKD
DAAs: high real-world efficacy in HCV/HIV coinfection
Prevalence of HEV antibodies in NZ blood donors
Identify and treat alcohol misuse in HCV

Please login below to download this issue (PDF)